Indeed, when comparing adjMAFs of PIK3CA and KRAS in CRC samples with co‐occurring mutations (Fig. S1A), we confirmed that potential subclonality of PIK3CA mutations is restricted to a subset of CRC tumors (32 of 86 samples [37.2%] with KRAS/PIK3CA adjMAFs ratio > 1.5). This evidence concerns the gene PIK3CA and colorectal carcinoma.